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http://dx.doi.org/10.1016/j.pedneo.2Background: The purpose of this study is to compare the effects and complications of pharma-
cologic closure of patent ductus arteriosus (PDA) by intravenous indomethacin or oral
ibuprofen in neonates weighing <1500 g at birth [very low birth weight (VLBW) infants].
Methods: This is a retrospective study of infants treatedwith intravenous indomethacin (0.2mg/
kg initially followed by two doses at 24-hour intervals) or oral ibuprofen (10 mg/kg initially fol-
lowed an interval of 24 hours by two doses of 5 mg/kg) for symptomatic PDA in a neonatal inten-
sive care unit at amedical center in Taiwan during the period of January 2005 to December 2010.
Results: A total of 88 infants received indomethacin and 52 received oral ibuprofen. Among the
survivors, the closure ratewithout surgical ductal ligationwas 70.5% (62/88) in the indomethacin
group and 61.5% (32/52) in the ibuprofen group (pZ 0.342). The incidence rates of oliguria and
elevated serum creatinine were significantly lower in the ibuprofen group (p Z0.002 and
pZ0.022, respectively). There was no significant difference in incidence of upper gastrointes-
tinal hemorrhage or necrotizing enterocolitis between the ibuprofen and indomethacin groups
(17.3% versus 23.9%; 3.8% versus 11.3%).
Conclusion: In infants with VLBW, oral ibuprofen is as effective as intravenous indomethacin for
closure of PDA and is associated with significantly fewer cases of necrotizing enterocolitis among
infantswith birth bodyweights<1250 g and significantly lower rates of elevated creatinine levels
among neonates with birth body weights ranging from 1000 to 1500 g.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.u Street, Changhua, Taiwan.
(H.-N. Chen).
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Oral ibuprofen vs. IV indomethacin with PDA 3471. Introduction closure and complication has been the end of the initialThe incidence of patent ductus arteriosus (PDA) in prema-
ture, very low birth weight (VLBW) infants (birth weight
<1500 g) is approximately 30%.1 The hemodynamic effects
consist of disturbances in the diastolic flow of the pulmo-
nary artery and the aorta and disturbances in the diastolic
flow of the cerebral and mesenteric perfusion, which
increase the risk for intraventricular hemorrhage (IVH) and
gastrointestinal bleeding.2 More than two thirds of infants
with a birth weight below 1750 g require either medical or
surgical closure of PDA.3 Treatment options include medical
therapy and surgical ligation.4,5 Medical closure of PDA can
be achieved with nonselective cyclooxygenase inhibitors,
such as indomethacin and ibuprofen, which block the
conversion of arachidonic acid to prostaglandins.5,6 Treat-
ment with indomethacin is associated with adverse events
such as reduced renal, mesenteric, and cerebral
perfusion.7e9 Unlike indomethacin, ibuprofen has fewer
effects on renal perfusion.10e12
In April 2006, intravenous ibuprofen was introduced as
an alternative agent in the United States; however, its use
was suspended in early 2010.13 Intravenous ibuprofen is not
available in most countries and is much more expensive
than the oral form. Oral ibuprofen has been used for
closure of PDA since early 2000.14 The availability and lower
cost of oral ibuprofen has led many physicians to use that
regimen for closure of PDA.15e19Although oral ibuprofen is
used widely, few randomized studies have compared its
efficacy and safety with intravenous indomethacin, espe-
cially among infants in different VLBW categories.18,20,21
The purpose of this study was to compare the efficacy
and complications of intravenous indomethacin with those
of oral ibuprofen in closure of PDA among infants in
different VLBW categories.
2. Materials and Methods
2.1. Patients
This retrospective study was conducted in the neonatal
intensive care unit of the Changhua Christian Hospital of
Changhua city in Taiwan during the period of January 2005
to December 2010. The inclusion criteria included a birth
body weight <1500 g, a postnatal age between 48 and 96
hours, and echocardiographic evidence of left-to-right
shunting across the ductus arteriosus with sign(s) of heart
failure (respiratory distress, apnea, tachycardia, bounding
pulse, and widened pulse pressure). Infants who died within
3 days after birth, those with echocardiographic evidence
of right-to-left shunting, infants with major congenital
anomalies, and those with IVH grade 3 or 4 were excluded.
2.2. Study design
Clinical data and information were collected from the
medical records of the enrolled infants and included the
response to intravenous indomethacin or oral ibuprofen
(closed or failed), the need for surgical ligation, and
adverse effects associated with indomethacin oribuprofen. The endpoint for medical therapy of PDA
medical treatment. Adverse events included oliguria
(urine output <1 mL/kg/hour), post-treatment (within 1
week after treatment) serum creatinine levels > 1.2 mg/
dL, necrotizing enterocolitis (NEC), coffee-ground aspi-
rate, or fresh blood aspirated through the gastric tube.
These signs were considered to be adverse events of
therapy if they occurred during the treatment course or
within 48 hours after treatment. In clinical practice, if the
patient was unsuitable for medical treatment or more
serious complications occurred, they underwent surgical
PDA ligation.
During the study period, routine echocardiographic
screening of infants with birth weights <1500 g was per-
formed between 48 and 96 hours after birth. Infants with
respiratory distress, increased oxygen requirements,
apnea, tachycardia, bounding pulse, widened pulse pres-
sure, or evidence of renal dysfunction were considered to
have symptomatic PDA.
Infants who received intravenous indomethacin were
stratified into Group I. Intravenous indomethacin was given
in three doses at 24-hour intervals depending on patient
age (<48 hours of life, 0.2 mg/kg, 0.1 mg/kg, and 0.1 mg/
kg; 2e7 days of life, 0.2 mg/kg; and > 7 days of life,
0.2 mg/kg, 0.25 mg/kg, and 0.25 mg/kg).
Infants who received oral ibuprofen were stratified into
Group O. Oral ibuprofen (Idofen, standard, Taiwan; 1 mL
equals 20 mg of ibuprofen, pH: 4.6) was given in three
doses: 10 mg/kg, 5 mg/kg, and 5 mg/kg with a 24-hour
interval between each dose. Ibuprofen was administered
through an oral-gastric tube, followed by flushing with
distilled water. Contraindications to either agent included
serum creatinine > 1.7 mg/dL or platelet count <70,000/
mm3. The indication of PDA ligation included a contraindi-
cation to medical therapy, oliguria, gastrointestinal
bleeding, and pulmonary hemorrhage.
2.3. Subgroup analysis
Infants in Group O and those in Group I were subdivided into
three subgroups according to birth weight: <1000 g,
1000e1249 g, and 1250e1499 g.
2.4. Outcome
The primary outcome in our study was closure of PDA.
Treatment failure in Group O was defined in patients that
required intravenous indomethacin or surgical ligation
after initial treatment with oral ibuprofen. Treatment
failure in Group I was defined in patients that required
surgical ligation or required conversion to oral therapy
after initial treatment with intravenous indomethacin.
Secondary outcomes included the development of oliguria
(urine out put <1 mL/kg/hour), elevated serum creatinine
(Cr > 1.2 mg/dL), NEC (any stage, radiographic signs
include dilated bowel loops, paucity of gas, a “fixed
loop,” or pneumatosis intestinalis, according to Bell
classification of NEC), or upper gastrointestinal bleeding
(fresh blood and/or coffee-ground aspirate from the
nasogastric tube).
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Data were analyzed according to the intention-to-treat
principle. Statistical analysis of data was performed using
the Chi-square test, the Mann Whitney U test, or Fisher’s
exact test. Relative risk and 95% confidence intervals were
estimated by Poisson regression with robust error variance.
Continuous data, such as weight, gestational age, serum
blood urea nitrogen and Cr levels, and urine output are
presented as mean  standard deviation. A p value of
<0.05 was considered to indicate statistical significance.
All statistical analyses were performed on a personal
computer with the statistical package SPSS for Windows
(Version 15.0, SPSS, Chicago, IL, USA).3. Results
During the period of January 2005 to December 2010,
a total of 468 very low birth weight infants survived to the
third day of hospitalization in the neonatal intensive care
unit of the Changhwa Christian Hospital. Among them,
185 (39.5%) had Doppler-ultrasonographic evidence of
PDA. Five infants were excluded, three for right-to-left
shunting and two for severe IVH. PDA spontaneously
closed without pharmacologic treatment after fluid
restriction in 26 infants and 14 sick infants received
surgical ligation without medical therapy. A total of 88
infants received intravenous indomethacin and 52 infants
were treated with oral ibuprofen (Figure 1). The baseline
characteristics were similar between both groups of
neonates (Table 1).3.1. Primary outcome
Closure of PDA was achieved in 32 (61.5%) of the infants in
the oral ibuprofen group and in 62 (70.5%) of the infants in
the intravenous indomethacin group (p Z 0.342, Table 2).
The subgroup analysis revealed that oral ibuprofen treat-
ment was more effective at closing PDA in patients with
higher birth body weights (closure rate: 71.4% in infants
weighing 1250e1499 g; 69.2% for infants weighing
1000e1249 g; and 44.4% for infants weighing <1000 g);
however, there was no significant difference in the rate of
closure between the three subgroups (Table 2).
In Group I, failure to close the PDA with intravenous
indomethacin occurred in three infants (3.4%), although
closure was achieved after the regimen was switched to
oral ibuprofen therapy. In Group I, 26.1% (23/88) of the
infants required surgical PDA ligations after failure of
medical therapy. Among them, oliguria occurred in 11
infants, UGI bleeding occurred in five, and NEC in three.
In Group O, failure to close the PDA with oral ibuprofen
occurred in 11 infants (21.2%) although the PDA was
closed successfully in those neonates after the regimen
was switched to intravenous indomethacin therapy. Nine
infants (17.3%; 9/52) in Group O received surgical PDA
ligation after failure of medical treatment (Figure 2).
Among the nine infants, one infant developed oliguria,
two infants developed UGI bleeding, and none dev-
eloped NEC.3.2. Secondary outcome
The incidence of elevated serum creatinine was signifi-
cantly lower in Group O than in group I [pZ 0.022, relative
risk (RR) Z 0.308, 95% confidence interval (CI):
0.112e0.844; (Table 3)]. The subgroup analysis revealed
that serum creatinine levels were significantly lower among
patients in Group O with birth body weights ranging from
1000 g to 1249 g (p＜0.001) and among those with weights
ranging from 1250 to 1499 g (p ＜ 0.001) than among their
counterparts in Group I.
During the first week after treatment, oliguria devel-
oped in nine infants (9.6%) in Group O and in 33 infants
(37.5%) in Group I (p Z 0.002, RR Z 0.256, 95% CI:
0.107e0.616; Table 3). Urine output (g/kg/hour) was
significantly higher among infants in Group O on Days 3e7 of
therapy (1.79  0.61 vs. 1.44  0.74, p Z 0.002). The
subgroup analysis revealed that urine output was signifi-
cantly higher among infants with birth body weights
> 1000 g than among infants in the other two body weight
categories (p Z 0.035).
The incidence rates of upper gastrointestinal hemor-
rhage and NEC were lower in Group O than in Group I (17.3%
vs. 23.9%; 3.8% vs. 11.4%, Table 4); however, there was no
significant difference in incidence of those two adverse
events between the three birth body weight subgroups
(Table 4).
There was no significant difference in incidence of NEC
between infants in Group O and those in Group I; however,
in the subgroup analysis, the incidence of NEC between
infants in Group O and those in Group I was significantly
lower in patients with birth body weights ranging from 1000
to 1249 g (p < 0.001) and in infants weighing > 1000 g
(p < 0.001) than in neonates with a birth body weight
ranging from 1250 to 1499 g (Table 4).4. Discussion
Clinical studies have shown that intravenous ibuprofen is as
effective as indomethacin for the treatment of PDA in
preterm infants.6,12 Intravenous ibuprofen is not available
in most countries and is more expensive than the oral form.
If oral ibuprofen were proved to be as efficient as intra-
venous indomethacin with no greater adverse effects, then
its simple administration and lower cost would be impor-
tant advantages.22 Our study was designed with sufficient
power for determining whether oral ibuprofen and intra-
venous indomethacin treatments are equally efficacious in
PDA closure.
The incidence of PDA in VLBW infants in our study was
approximately 30%, a rate that is similar to that reported
previously.1 The closure rate of PDA with intravenous
indomethacin (70.5%) in our study was similar to that re-
ported by Van Overmeire.6 Our study indicated that PDA
closure with oral ibuprofen in VLBW infants is at least as
effective as closure with intravenous indomethacin.
Recent meta-analyses of studies that compared intra-
venous ibuprofen with indomethacin therapy for PDA
closure in preterm infants revealed that intravenous
ibuprofen and intravenous indomethacin are equally
effective.23e26 A recent Cochrane review of 20 studies
88 infants received 
intravenous indomethacin 
52 infants received 
oral ibuprofen 
185 premature infants with PDA by cardiac ultrasound 
140 infants with symptomatic PDA 
5 were excluded 
-- Right-to-left shunting: n = 3 
-- Severe IVH: n = 2 
14 underwent PDA ligation without 
medical therapy 
-- Renal failure: n = 7 
-- Pulmonary hemorrhage: n = 5 
-- Gastrointestinal bleeding: n = 2 
26 PDA spontaneous closure 
506 admitted VLBW infants 
468 live VLBW infants on 3rd days 
Figure 1 Infants enrolled in the study protocol.
Table 1 Baseline characteristics of the study infants.
Characteristic Group O (N Z 52) Group I (N Z 88) p value
Gestational age, mean  SD, wk 28.76  2.28 (24e33.86) 28.93  2.23 (23.57e33.86) 0.703
Birth weight, mean  SD, g 1129.74  240 1130.6  222.5 0.902
<1000, n (%) 18 (34.6) 27 (30.7) 0.449
1000e1249, n (%) 13 (25) 31 (35.2) 0.46
1250e1499, n (%) 21 (40.4) 30 (34.1) 0.384
Sex
Male, n (%) 29 (55.8) 43 (48.9) 0.43
Female, n (%) 23 (44.2) 45 (51.1) 0.43
Delivery by cesarean section, n (%) 36 (69.2) 56 (63.6) 0.5
Group O: treated with oral ibuprofen. Group I: treated with intravenous indomethacin. Data are presented as mean  SD (range) or
number (%).
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Table 2 Oral ibuprofen and intravenous indomethacin for closure of PDA.
Variable Group O (N Z 52) Group I (N Z 88) p value Relative risk (95% confidence interval)
Closure of PDA, n (%)
Overall 32 (61.5) 62 (70.5) 0.342 0.872 (0.69-1.15)
Birth weight, g
<1000, n (%) 8/18 (44.4) 12/27 (44.4) 1.0 1.00 (0.51e1.95)
1000e1249, n (%) 9/13 (69.2) 25/31 (80.6) 0.456 0.858 (0.58e1.28)
1250e1499, n (%) 15/21 (71.4) 25/30 (83.3) 0.493 0.857 (0.65e1.24)
Group O: treated with oral ibuprofen. Group I: treated with intravenous indomethacin. Data are presented as mean  SD (range) or
number (percent). PDA Z patent ductus arteriosus.
350 C.H. Lee et al(nZ 956 infants) reported that ibuprofen (oral form, initial
dose of 10 mg/kg followed by 5 mg/kg 24 and 48 hours
later) was as effective as indomethacin (intravenous form,
0.2 mg/kg every 12 hours for three doses) in closing PDA
and that ibuprofen reduces the risk of developing NEC and
transient renal insufficiency.26
Oral ibuprofen for closure of PDA in premature infants
was first used by Hariprasad14 in 13 infants in 2000. Since
then, a number of trials have been conducted to evaluate
the efficacy of oral ibuprofen for closure of PDA.17,18,21,27,28
The sample sizes in all of those studies, however, were
relatively small. In a randomized controlled study, Fakh-
raee et al19 found that PDA was successfully closed in all 18
premature infants (<34 weeks of gestation) who received
oral ibuprofen and that closure of the PDA was achieved in
15 of 18 premature infants who had been given oral indo-
methacin (p < 0.05).
The results from a number of clinical trials have
demonstrated that there is no significant difference in the
rate of closure of PDA in preterm infants between oral
ibuprofen and intravenous ibuprofen.15e17,22,29 However,
Chotigeat et al20 and Supapannachart et al21 found that oral
ibuprofen was more effective than intravenous indometh-
acin at closing PDA. In nonrandomized open trials, oral
ibuprofen was associated with a ductal arteriosus closure
rate of 95% (38 of 40 infants) in a study by Cherif et al,15
a closure rate of 95.4% (21 of 22 infants) in a study by62 PDA 
closed 
26 failed 
3 received oral 
ibuprofen 
23 surgical 
ligation 
PDA
closed 
PDA 
closed 
88 infants received 
intravenous 
indomethacin 
Figure 2 Flow chHeyman et al,27 and a closure rate of 84.6% (11 of 13
infants) in a study by Hariprasad et al.14 Ohlsson et al26
reviewed a total of 7 studies (n Z 189 infants) and found
that there was no significant difference in failure rate of
PDA closure between infants who received oral ibuprofen
and infants who were treated with intravenous
indomethacin.
The endpoint of this study was the end of the initial
medical treatment. In clinical practice, if the patient was
unsuitable for medical treatment, surgical PDA ligation was
performed. According to our study, the study group who
received oral ibuprofen rarely required further surgical PDA
ligations. This phenomenon would be related to lower
complications from oral ibuprofen treatments.
Although a few studies have found that intravenous
ibuprofen was associated with a higher rate of PDA closure
than intravenous indomethacin among those VLBW infants
with higher birth body weights,30,31 our study, to the best of
our knowledge, is the first study to compare the effec-
tiveness of orally administered ibuprofen with that of
intravenously administered indomethacin at closing PDA
among preterm infants stratified by birth body weight. We
found that the rate of closure of PDA tended to be higher
among infants with a higher birth body weight in both
treatment groups. There was no significant difference in
closure rate between patients that received oral ibuprofen
and those that received intravenous indomethacin in each52 infants received 
oral ibuprofen 
32 PDA 
closed 
20 failed 
11 received iv 
indomethacin 
9 surgical 
ligation
PDA
closed 
PDA
closed 
art of therapy.
Table 3 Incidence of elevated serum creatinine and oliguria.
Variable Group O (N Z 52) Group I (N Z 88) p value Relative risk (95% confidence interval)
Elevated serum creatinine, n (%)
Overall 4 (7.7) 22 (25.0) 0.022 0.308 (0.11e0.84)
Birth weight, g
<1000, n (%) 4/18 (22.2) 11/27 (40.7) 0.224 0.55 (0.21e1.45)
1000e1249 g, n (%) 0/13 (0) 9/31 (29.0) <0.001 d
1250e1499 g, n (%) 0/21 (0) 2/30 (6.7) <0.01 d
Oliguria, n (%)
Overall 5 (9.6) 33 (37.5) 0.002 0.256 (0.107e0.616)
Birth weight, g
<1000, n (%) 2/18 (11.1) 13/27 (48.1) 0.035 0.231 (0.059e0.903)
1000e1249, n (%) 2/13 (15.4) 10/31 (32.3) 0.291 0.477 (0.121e1.883)
1250e1499, n (%) 1/21 (4.8) 10/30 (33.3) 0.054 0.143 (0.02e1.033)
Group O: treated with oral ibuprofen. Group I: treated with intravenous indomethacin. Data are presented as mean  SD (range) or
number (percent).
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closure among preterm infants who received medical
treatment with higher birth body weights may be mean-
ingful in clinical practice. However, the relatively small
number of patients in each subgroup limited the power of
our study to detect significant differences. Large sample
and prospective randomized studies are certainly needed
to validate these findings.
Premature babies with immature organ systems are
more susceptible to pharmacological interactions. Tiker
et al32 reported that oral ibuprofen therapy was associated
with acute renal failure in extremely low birth weight
(ELBW) infants. In our analysis, five infants developed oli-
guria and four infants had elevated serum Cr levels after
oral ibuprofen therapy. The majority of those patients were
ELBW infants. As can be seen from the above results, the
lower body weight premature infants are more susceptible
to pharmacologic complications. In our analysis, the inci-
dence of associated renal complications such as oliguria or
elevated serum Cr levels was lower in the oral ibuprofenTable 4 Incidence of upper gastrointestinal bleeding and necro
Variable Group O (N Z 52) Group I (N Z 8
UGI bleeding, n (%)
Overall 9 (17.3) 21(23.9)
Birth weight, g
<1000, n (%) 3/18 (16.7) 6/27 (22.2)
1000e1249, n (%) 2/13 (15.4) 10/31 (32.3)
1250e1499, n (%) 4/21 (19.0) 5/30 (16.7)
Necrotizing enterocolitis, n (%)
Overall 2 (3.8) 10 (11.4)
Birth weight, g
<1000, n (%) 0/18 (0) 4/27 (14.8)
1000e1249, n (%) 0/13 (0) 5/31 (16.1)
1250e1499, n (%) 2/21 (9.5) 1/30 (3.3)
Group O: treated with oral ibuprofen. Group I: treated with intraven
number (%).group than in the intravenous indomethacin group. In
addition, the incidence of oliguria was significantly lower in
the extremely low birth weight subgroup that received oral
ibuprofen. It appears that oral ibuprofen resulted in fewer
renal adverse events than intravenously administered
indomethacin. Chotigeat et al20 and Supapannachart et al21
also reported that oral ibuprofen resulted in fewer renal
adverse events than oral or intravenously administered
indomethacin. Clinicians should be vigilant for complica-
tions of acute renal failure in treatment of PDA closure by
given oral ibuprofen, especially in ELBW infants. Even the
incidence of associated renal complications was lower in
the oral ibuprofen group than the intravenous indometh-
acin group for the treatment of PDA closure.
Upper gastrointestinal hemorrhage and NEC are common
sequelae in preterm infants with PDA.33 In our study, the
incidence rates of gastrointestinal hemorrhage and NEC
were lower among infants who received oral ibuprofen,
although there was no significant difference in the devel-
opment of those sequelae between patients that receivedtizing enterocolitis after medical PDA therapy.
8) p value Relative risk (95% confidence interval)
0.37 0.725 (0.36-1.463)
0.652 0.75 (0.215e2.62)
0.291 0.477 (0.121e1.883)
0.826 1.143 (0.347e3.759)
0.151 0.338 (0.077e1.485)
<0.001 d
<0.001 d
0.378 2.857 (0.277e29.51)
ous indomethacin. Data are presented as mean  SD (range) or
352 C.H. Lee et aloral ibuprofen and infants that received intravenous indo-
methacin. None of the infants who received oral ibuprofen
treatment in our study showed evidence of bowel perfo-
ration. The rate of NEC among our infants who received
enteral ibuprofen was similar to that reported by Tulin
et al,22 but it was below the overall rate reported for
intravenous ibuprofen [27/356 (8%)] in a recent meta-
analysis of studies on preterm infants with HsPDA.34 In
our infants, the drug was given undiluted through a feeding
tube in a very small volume followed by flushing with
distilled water. The pH of the ibuprofen suspension used in
our study was 4.6, which is not associated with gastroin-
testinal irritation. Toleration of the oral form of ibuprofen
was better than that of intravenously administered indo-
methacin in terms of gastrointestinal complications such as
intestinal perforation or bleeding and NEC.
There are limitations in applying the results of our study
because of its retrospective design, power and sample size.
Although the infants in our study were not randomized, the
characteristics of the infants in the two groups were similar
and there were no major changes in clinical practice during
the 6-year study period. Despite these limitations, the final
result still contributes valuable information on the feasi-
bility of using oral ibuprofen in treatment of PDA closure in
premature infants.
5. Conclusions
In VLBW infants, oral ibuprofen is as effective as intrave-
nous indomethacin for closure of PDA and is associated with
significantly fewer cases of necrotizing enterocolitis among
infants with birth body weights <1250 g and significantly
lower rates of elevated creatinine levels among neonates
with birth body weights ranging from 1000 to 1500 g. Larger,
prospective randomized studies are needed to clarify the
efficacy and safety of oral ibuprofen with the efficacy and
safety of other medical treatments for closure of PDA in
infants with premature extremely low birth weight infants.
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